On October 15, I joined Voters for Cures patient advocate Cristi Waltz at Reuters Pharma and Patient USA 2024 where we discussed her experience with autoimmune hemolytic anemia (AIHA). Both Cristi and her grandson have this rare immune disorder.
She spoke about the barriers that insurers and their middlemen have placed between them and their treatments, including steering them to their own pharmacy. That forced them to travel more than 8 hours roundtrip each month to pick up her grandson’s medicine. She also talked about the difficulties she experienced with the “fail first” requirements her insurance put her through, making her try other treatments first before they approved the one her doctor recommended. Policymakers must take action to hold insurers and pharmacy benefit managers (PBMs) accountable by breaking the link between PBM compensation and the list price of medicines and passing on negotiated savings to patients.
I was also inspired by Cristi’s hope for future scientific advancements for diseases like AIHA. While her grandson is stable today, and the outlook for patients with AIHA is good, therapy changes or adjustments are sometimes needed. New innovations that minimizes side effects and improves long-term prognosis are her hope. But she is concerned about policies that may hinder future R&D and put patients like her and her grandson at risk. We must safeguard our strong IP protections, efficient regulatory system, competitive market and incentives that allow public and private entities to collaborate—fostering innovation that allows patients to live longer, healthier lives.
Thanks to Cristi for sharing her story – it is a reminder of why patient experiences must inform how we approach policy reform.
Read more about the Voters for Cures program here: https://votersforcures.org/
Mike Ybarra
Michael Ybarra, M.D., is an emergency physician and Chief Medical Officer at PhRMA. He also serves as Senior Vice President in Advocacy and Strategic Alliances. In these roles, he leads PhRMA’s stakeholder engagement and strategic partnerships on federal and international health policy issues. He is PhRMA’s liaison representative to the Advisory Committee on Immunization Practices and is the co-convener of PhRMA’s R&D Leadership Forum. Dr. Ybarra continues to see patients clinically in the emergency department at MedStar Georgetown University Hospital.
Follow Mike on LinkedIn and X.
Mike Ybarra
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
Insurers blame GLP-1s for rising costs. The data tells a different story.
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
PBMs/Insurance
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes